Rexahn Pharmaceuticals, Inc.
Records under this name other than patents Rexahn Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Rexahn Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,150,520 | Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE Formerly held In force · High confidence | In force | High confidence | |
| US 9,533,958 | Process or the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-Enyl)-1H-pyrimidin-2-one Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,920,016 | Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-Cyclopent-2-Enyl)-1H-Pyrimidin-2-One Formerly held In force · Low confidence | In force | Low confidence | |
| US 9,782,410 | Fluorocyclopentenylcytosine methods of use Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,278,971 | Fluorocyclopentenylcytosine methods of use Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,405,214 | Nucleoside derivatives and therapeutic use thereof Formerly held Term ended Term ended Aug 24, 2025 · From the USPTO record | Term ended | Term ended Aug 24, 2025 | From the USPTO record |
| US 7,205,283 | Antisense oligonucleotides that inhibit expression of HIF-1 Formerly held Term ended Term ended Jun 16, 2025 · From the USPTO record | Term ended | Term ended Jun 16, 2025 | From the USPTO record |
| US 7,388,014 | Quinazoline derivatives and therapeutic use thereof Formerly held Term ended Term ended Feb 17, 2025 · From the USPTO record | Term ended | Term ended Feb 17, 2025 | From the USPTO record |
| US 7,122,527 | Use of antisense oligonucleotides to inhibit the expression of human Akt-1 Formerly held Term ended Term ended Feb 10, 2025 · From the USPTO record | Term ended | Term ended Feb 10, 2025 | From the USPTO record |
| US 8,314,100 | 1-[6,7-Substituted Alkoxyquinoxalinyl) AMINOCARBONYL]-4-(HETERO) Arylpiperazine Derivatives Formerly held Lapsed on the fee record Ended Nov 20, 2024 · High confidence | Lapsed on the fee record | Ended Nov 20, 2024 | High confidence |